公开(公告)号：US10508108B2

公开(公告)日：2019-12-17

申请号：US15532552

申请日：2015-12-01

申请人： Merck Sharp & Dohme Corp.

发明人： Christian Fischer ,  Stephane L. Bogen ,  Matthew L. Childers ,  Francesc Xavier Fradera Llinas ,  J. Michael Ellis ,  Sara Esposite ,  Dawn M. Hoffman ,  Chunhui Huang ,  Solomon D. Kattar ,  Alexander J. Kim ,  John W. Lampe ,  Michelle R. Machacek ,  Daniel R. McMasters ,  Dann L. Parker, Jr. ,  Michael H. Reutershan ,  Nunzio Sciammetta ,  Pengcheng P. Shao ,  David L. Sloman ,  Wanying Sun ,  Feroze Ujjainwalla ,  Zhicai Wu ,  Yang Yu ,  Craig R. Gibeau

IPC分类号： C07D471/04 ,  C07D471/14 ,  C07D519/00

摘要： The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is —C(R1)═ or —N═; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

公开(公告)号：US20170362220A1

公开(公告)日：2017-12-21

申请号：US15532552

申请日：2015-12-01

申请人： Merck Sharp & Dohme Corp.

发明人： Christian Fischer ,  Stephane L. Bogen ,  Matthew L. Childers ,  Francesc Xavier Fradera Llinas ,  Michael J. Ellis ,  Sara Esposite ,  Dawn M. Hoffman ,  Chunhui Huang ,  Solomon D. Kattar ,  Alexander J. Kim ,  John W. Lampe ,  Michelle R. Machacek ,  Daniel R. McMasters ,  Dann L. Parker, Jr. ,  Michael H. Reutershan ,  Nunzio Sciammetta ,  Patrick Pengcheng Shao ,  David L. Sloman ,  Wanying Sun ,  Feroze Ujjainwalla ,  Zhicai Wu ,  Yang Yu ,  Craig R. Gibeau

IPC分类号： C07D471/04 ,  C07D519/00 ,  C07D471/14

CPC分类号： C07D471/04 ,  C07D471/14 ,  C07D519/00

摘要： The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is —C(R1)═ or —N═; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.